Drug Trial Radar · NCT05923099
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
262
Actual
Start
Sep 20, 2023
Primary completion
Dec 11, 2024
Study completion Apr 9, 2025
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jun 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to test different doses of the trial medicine (LEO 138559) and see how well they work and how safe they are at treating moderate to severe atopic dermatitis in adults. There will be 4 different doses, that will also be compared to a placebo (a dummy medicine that doesn't contain the active ingredient of LEO 138559). Each participant will be randomly assigned to one of the 4 doses of LEO 138559 or placebo. In all arms, injections of placebo may be used to mask the different doses. The trial will last up to 36 weeks, including a screening/washout period (up to 4 weeks), a treatment period (16 weeks), and a follow up period (16 weeks). The participants will visit the clinic 17 times. For the first 4 weeks of the treatment period, participants will visit the clinic every week. For the next 12 weeks of the treatment period, participants will visit the clinic every 2 weeks. For the 16 week follow up period, participants will visit the clinic every 4 weeks. The treatments will be given to the participants by staff at the clinic. They are given as an injection just under the skin. At each visit the doctor will check the participants atopic dermatitis and if they have had any side effects. Participants will also complete an electronic diary every day about their atopic dermatitis and quality of life. LEO 138559 is also called "Temtokibart".
Conditions
- Atopic Dermatitis
Interventions
LEO 138559Drug
LEO 138559 given by injection just under the skin
PlaceboDrug
Placebo given by injection just under the skin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Eczema Area and Severity Index (EASI) ScoreTime frame: From baseline to Week 16
Locations
73 sites in 11 countries. Site status is shown where the registry gives one.
LEO Investigational Site
Fountain Valley, California
LEO Investigational Site
Los Angeles, California
LEO Investigational Site
San Francisco, California
LEO Investigational Site
Hialeah, Florida
LEO investigational site
Indianapolis, Indiana
LEO investigational Site
New Albany, Indiana
LEO Investigational Site
Ann Arbor, Michigan
LEO Investigational Site
New York, New York
LEO Investigational Site
Raleigh, North Carolina
LEO Investigational Site
Cincinnati, Ohio
LEO Investigational Site
Mayfield Heights, Ohio
LEO Investigational Site
North Charleston, South Carolina
LEO Investigational Site
Edmonton, Albana, Canada
LEO Investigational Site
Calgary, Alberta, Canada
LEO Investigational Site
Calgary, Alberta, Canada
LEO Investigational Site
Edmonton, Alberta, Canada
LEO Investigational Site
Surrey, British Columbia, Canada
LEO Investigational Site
Mississauga, Ontario, Canada
LEO Investigational Site
Sherbrooke, Quebec, Canada
LEO Investigational Site
Verdun, Quebec, Canada
LEO Investigational Site
Náchod, Czechia
LEO Investigatonal Site
Ostrava-Poruba, Czechia
LEO Investigational Site
Prague, Czechia
LEO Investigational Site
Prague, Czechia
LEO Investigational Site
Dijon, France
LEO Investigational Site
Nice, France
LEO Investigational Site
Paris, France
LEO Investigational Site
Rouen, France
LEO Investigational Site
Martigues, Bouches-du-Rhône, France
LEO Investigational Site
Augsburg, Germany
LEO Investigational Site
Bad Bentheim, Germany
LEO Investigational Site
Berlin, Germany
LEO Investigational Site
Dresden, Germany
LEO Investigational Site
Frankfurt am Main, Germany
LEO Investigational Site
Freiburg im Breisgau, Germany
LEO Investigational Site
Gera, Germany
LEO Investigational Site
Kiel, Germany
LEO Investigational Site
Leipzig, Germany
LEO Investigational Site
Mahlow, Germany
LEO Investigational Site
Münster, Germany
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.